Results: Natalizumab patients had a net improvement in disability over time (-0.15 EDSS years) while placebo had a net worsening (+0.33 EDSS years), as measured by LS mean AUC; the difference (0.48 EDSS years) was highly significant ( P < 0.0001).
Results: Among the 5 subjects, there were 132 nominally significant correlations (p< 0.05) between mRNA expression and MRI activity.
ARCS scores showed a trend to decline over time especially the memory domain (p=0.06) however no difference between the DMT groups was found.
Although not statistically significant, D-FIS approached significance (p = 0.066) as a potential moderator when examining informant ratings of cognition and mood (Adjusted R 2 = 0.094).
A tendency towards significance was found with SDMT (r=0.359; p=0.078).
Similarly, the levels of IFN-g and TNF-a proinflammatory cytokines were decreased in all groups of sema7AKO mice, although the differences did not reach statistical significance respect to those observed in WT mice.
CDP6M was also significantly reduced for PEG-IFN Q2W versus IFN beta-1a 30 μg (HR 0.46 [95% CI: 0.226-0.943]), with a numerical trend favoring PEG-IFN Q2W versus other IFNs assessed for ARR, and versus all other injectables for CDP6M.
Patients who were younger at disease onset (r = 0.38, p = 0.054) and had a higher T1-weighted lesion volume (r = −0.32, p < 0.10) had lower accuracy on the GNG task, trending towards significance.